{
  "attach_pages": "3",
  "attach_size": "282",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201802281095415706_1.pdf?1519827936000.pdf",
  "company_code": "80000119",
  "eitime": "2018-02-28 14:25:57",
  "extend": {},
  "info_code": "AP201802281095415706",
  "language": "0",
  "notice_date": "2018-02-28 00:00:00",
  "notice_title": "业绩如预期恢复，长期将受益于创新药CRO需求提升",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "researcher": "王睿哲",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "727",
          "publishName": "医疗服务"
        }
      ],
      "short_name": "泰格医药",
      "short_name_ch": "泰格医药",
      "short_name_cht": "泰格醫藥",
      "short_name_en": "TIGERMED",
      "stock": "300347"
    }
  ],
  "short_name": "泰格医药",
  "source_sample_name": "群益证券",
  "star": "1"
}